Q4 2024 Kamada Ltd Earnings Call Transcript
Key Points
- Kamada Ltd (KMDA) reported record financial results for 2024, with total revenue reaching $161 million, a 13% increase over 2023.
- Adjusted EBITDA for 2024 was a record $34.1 million, representing a 42% year-over-year growth.
- The company generated $47.6 million in cash from operations, resulting in a strong year-end balance sheet with $78.4 million in cash.
- Kamada Ltd (KMDA) declared a second cash dividend of $0.20 per share, reflecting confidence in its business prospects.
- The company successfully launched its first biosimilar product in Israel and plans to launch two additional biosimilars in 2025, with expectations of significant sales growth in this segment.
- Operating expenses increased to $49.9 million in 2024, primarily due to higher sales and marketing costs and increased R&D expenses.
- The reduction in net income in the fourth quarter of 2024 was attributed to increased financial expenses related to the revaluation of contingent consideration.
- The company's plasma collection centers are expected to take 24 to 30 months to reach full revenue potential, indicating a longer timeline for realizing returns.
- Kamada Ltd (KMDA) faces risks associated with its ongoing Phase III pivotal trial for inhaled AAT, including potential outcomes from a futility analysis.
- The company's growth strategy heavily relies on successful execution of M&A and business development transactions, which may not materialize as planned.
Greetings, and welcome to the Kamada fourth quarter and full year 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Brian Ritchie with LifeSci Advisors. Thank you, sir. You may begin.
Thank you. This is Brian Ritchie with LifeSci Advisors. Thank you all for participating in today's call. Joining me from Kamada are Amir London, Chief Executive Officer; and Chaime Orlev, Chief Financial Officer. Earlier today, Kamada announced its financial results for the three months and full year ended December 31, 2024.
If you have not received this news release, please go to the Investors page of the company's website at www.kamada.com. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements that involve risks and uncertainties regarding the operations
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
